Alpha-Synuclein Seed Amplification Assay Validation

V2, Crosslink

🧫

Alpha-Synuclein Seed Amplification Assay Validation

active

experiment Created: 2026-04-02T10:01:41 By: crosslink-v2 Quality: 67% ✓ SciDEX ID: experiment-exp-wiki-experiments-alpha-sy

🧫 Experiment Protocol Clinicalproposed

SUMMARY

# Alpha-Synuclein Seed Amplification Assay Validation ## Background and Rationale Alpha-synuclein aggregation is a hallmark pathological feature of Parkinson's disease (PD), with misfolded α-synuclein proteins forming Lewy bodies in affected neurons. Current PD diagnosis relies primarily on clinical symptoms that manifest after significant neurodegeneration has occurred, highlighting the critical need for early diagnostic biomarkers. Seed amplification assays (SAAs) represent a revolutionary app

METHODOLOGY NOTES

Phase 1 (Months 1-3): Standardize SAA protocol across 5 clinical centers using recombinant α-synuclein substrate (0.1 mg/mL), thioflavin-T fluorescent reporter (20 μM), and optimized buffer conditions (PBS pH 7.4, 150 mM NaCl). Establish sonication parameters (1-second pulses, 30% amplitude) and incubation cycles (42°C, 1-minute intervals). Phase 2 (Months 4-8): Recruit participants including 200 clinically diagnosed PD patients (Hoehn-Yahr stages 1-3), 100 prodromal cases (REM sleep behavior disorder, hyposmia), and 150 age-matched healthy controls. Collect CSF (2 mL) via lumbar puncture and plasma (5 mL) samples under standardized conditions. Process samples within 2 hours and store at -80°C. Phase 3 (Months 9-15): Execute SAA testing in duplicate across all centers. Load 20 μL sample aliquots into 384-well plates with positive controls (PD brain homogenate) and negative controls (buffer only). Monitor thioflavin-T fluorescence every 15 minutes for 60 hours using plate readers. Recor

▸Metadatasource: {'type': 'manual', 'source_name': 'wiki'

source	{'type': 'manual', 'source_name': 'wiki', 'extracted_by': 'backfill_v1', 'extraction_date': '2026-04-16T01:00:16.901459Z'}
summary	# Alpha-Synuclein Seed Amplification Assay Validation ## Background and Rationale Alpha-synuclein aggregation is a hallmark pathological feature of Parkinson's disease (PD), with misfolded α-synuclein
entities	{'genes': ['CLDN1/DNMT1/DRD2'], 'diseases': ["Parkinson's Disease"]}
model_system	human
_schema_version	1
experiment_type	clinical
primary_outcome	Establish diagnostic sensitivity and specificity of α-synuclein SAAs for PD detection, achieving >90% sensitivity and >85% specificity compared to clinical diagnosis and dopamine transporter imaging.
methodology_notes	Phase 1 (Months 1-3): Standardize SAA protocol across 5 clinical centers using recombinant α-synuclein substrate (0.1 mg/mL), thioflavin-T fluorescent reporter (20 μM), and optimized buffer conditions
replication_status	single_study
extraction_metadata	{'backfill_at': '2026-04-16T01:00:16.901463', 'needs_review': True, 'extraction_notes': 'Backfilled from wiki source (no PMID available)', 'extraction_confidence': 0.4}

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

704

Outgoing

640

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Alpha-Synuclein Seed Amplification Assay Validation

derives from (16)

supports (5)

💬 Discussion